Established prescription products
Sanofi’s (SNY) established prescription products portfolio reported revenues of ~2.3 billion euros in 4Q17, an ~5.5% decline in operating revenues compared to 4Q16. This decrease in revenues was due to the lower sales of Renagel, Lovenox, Allegra, Myslee, Synvisc, Lasix, Targocid, and several other prescription drugs.
However, the decline in revenues was partially offset by strong sales of Plavix, Aprovel, Depakine, and Tritace. The established prescription products are part of the General Medicines and Emerging Markets segment. The chart below shows the revenues for Sanofi’s established prescription products since 1Q16.
Plavix reported revenues of 348.0 million euros in 4Q17 for 2.5% growth in operating revenues compared to 4Q16. This growth was driven by strong sales in emerging markets, and it was substantially offset by lower sales from Europe and the rest of the world markets.
Lovenox reported revenues of 388.0 million euros in 4Q17, a 2.7% decline in operating revenues compared to 4Q16. This decline was driven by lower sales in the European markets, substantially offset by growth in US sales and sales from the rest of the world.
Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16. The decline was due to lower sales of Renagel/Renvela in all global markets excluding emerging markets.
Aprovel reported revenues of 158.0 million euros in 4Q17, reflecting 2.5% growth in operating revenues compared to 4Q16. This growth was driven by lower sales of Aprovel in all global markets excluding emerging markets.
The BLDRS Developed Markets 100 ADR ETF (ADRD) holds 17.4% of its total investments in healthcare companies. ADRD holds 2.1% in Sanofi ADR (SNY), 2.0% in AstraZeneca ADR (AZN), 2.2% in Novo Nordisk ADR (NVO), and 5.2% in Novartis AG ADR (NVS).